Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer
- Gritstone bio Inc (NASDAQ: GRTS) has announced updated results from the Phase 1/2 study of GRANITE individualized neoantigen immunotherapy in advanced solid tumors.
- The immunotherapy is a heterologous prime-boost in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab), and Yervoy (ipilimumab).
- The data were presented at the European Society of Medical Oncology (ESMO) Annual Meeting.
- In microsatellite-stable colorectal cancer (MSS-CRC) patients, where checkpoint inhibitors have shown minimal activity, GRANITE elicited a 44% molecular response rate in 9 evaluable patients.
- Patients who demonstrated molecular response had a median overall survival of over 17 months (median not reached). Those without molecular response exhibited a median overall survival of 7.8 months, consistent with expected outcomes in 3rd line treatment of MSS-CRC.
- Multiple patients remained on treatment for over six months with a lack of confirmed disease progression.
- Gritstone will advance GRANITE into a Phase 2/3 trial (single protocol) for the maintenance treatment of newly diagnosed metastatic MSS-CRC patients who have completed FOLFOX-bevacizumab induction therapy.
- The Company will also conduct a Phase 2 trial evaluating GRANITE in the adjuvant setting for stage 2/3 MSS-CRC patients with ctDNA+ after definitive surgery. The trials will begin in the first half of 2022.
- Price Action: GRTS shares are up 5.99% at $14.35 during the premarket session on the last check Friday.
- Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech News Health Care Small Cap Movers Trading Ideas General
